You are here: Industry Insights > biosimilar

News List

A Review of Oncology Biosimilars Products and Companies David Orchard-Webb
May 12, 2022
Biologics and biosimilars are large and generally complex therapeutics produced from living organisms.
Biosimilars 2020: Low Approvals, but Significant Advances Neeta Ratanghayra
March 18, 2021
2020 has been a tough year. The pandemic posed an array of challenges to the healthcare system and the global biopharmaceutical industry both rose to the challenges and seized opportunities.
Which Will Market the First Chinese-produced Trastuzumab Biosimilar: Sunshine Guojian or Henlius? PharmaSources/Dopine
June 15, 2020
HER2-positive breast cancer has a high degree of malignancy and fast progression. Trastuzumab is the standard first-line regimen for adjuvant, neoadjuvant and metastatic cancer treatment of HER2-positive breast cancer.
Polpharma Biologics Announces Approval of Europe’s First and Only Biosimilar for Multiple Sclerosis - Tyruko® (Natalizumab) B3C newswire
November 06, 2023
Polpharma Biologics, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.
Polpharma Biologics Announces FDA Approval of Tyruko® - First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple Sclerosis PharmaSources
August 28, 2023
On August 25, 2023,Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko®.
Polpharma Biologics Announces First-of-a-Kind Multiple Sclerosis Biosimilar Natalizumab Receives Positive CHMP Opinion PharmaSources
July 24, 2023
Polpharma biologics announces first-of-a-kind multiple sclerosis biosimilar natalizumab receives positive CHMP opinion.
Participants Dosed on Adessia in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa PharmaSources
March 07, 2023
Group in strategic collaboration with Divine Genes to offer genetic tests related to reproductive health in Malaysia and overseas.
Second Biosimilar Tocilizumab Injection approved for marketing www.nmpa.com
January 18, 2023
Second Biosimilar Tocilizumab Injection approved for marketing.
Biosimilar Tocilizumab Injection approved for marketing www.nmpa.com
January 16, 2023
Biosimilar Tocilizumab Injection approved for marketing.
2022 — a turning point for US biosimilars? CPhIonline
February 10, 2022
Cardinal Health says the majority of healthcare providers are keen to use biosimilars despite current market challenges.